Perceive Pharma, a pharmaceutical company pioneering novel small molecule therapeutics in ophthalmology, has announced the closing of a $15M Series A funding round including Deerfield Management, Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc.), Braidwell LP, GV, the Retinal Degeneration Fund, and Catalio Capital Management, LP.

Perceive Pharma是一家在眼科领域开创新型小分子疗法的制药公司，近日宣布完成了1500万美元的A轮融资，投资方包括Deerfield Management、强生（通过其企业风险投资机构Johnson & Johnson Innovation - JJDC, Inc.）、Braidwell LP、GV、视网膜退化基金和Catalio Capital Management, LP。

Perceive Pharma was spun out from Perceive Biotherapeutics to accelerate development of novel neuroprotective therapeutics in glaucoma and other indications. The Company also welcomes Carol Gallagher, Pharm.D. to the Perceive Pharma Board as an independent Board Director. .

Perceive Pharma从Perceive Biotherapeutics分拆出来，以加速青光眼及其他适应症的新型神经保护疗法的开发。公司还欢迎Carol Gallagher博士以独立董事会成员的身份加入Perceive Pharma董事会。

Perceive Pharma is advancing novel small molecule neuroprotective therapeutics, with lead pipeline programs in glaucoma and other ophthalmic diseases. Perceive was founded on compelling research that leveraged a comprehensive screening process in retina cells to identify maximally neuroprotective biological pathways.

Perceive Pharma正在推进新型小分子神经保护疗法，其主要研发项目集中在青光眼和其他眼科疾病。Perceive基于一项引人注目的研究成立，该研究利用视网膜细胞的全面筛选过程，以确定最具神经保护作用的生物通路。

The Company is backed by Deerfield Management, Johnson & Johnson Innovation, Braidwell LP, GV, Retinal Degeneration Fund, the venture arm of the Foundation Fighting Blindness, and Catalio Capital Management, LP..

公司得到了Deerfield Management、Johnson & Johnson Innovation、Braidwell LP、GV、视网膜退化基金（Retinal Degeneration Fund）、抗盲基金会（Foundation Fighting Blindness）的风险投资部门以及Catalio Capital Management, LP的支持。